Amgen to start its first CAR T trial in 1H18

Amgen Inc. (NASDAQ:AMGN) said it plans to start clinical testing of its first chimeric antigen receptor (CAR) T cell therapy this half. The trial will evaluate a single IV infusion of AMG 119 in about 41 patients with relapsed or refractory small cell lung cancer (SCLC) who have progressed after at least one platinum-based chemotherapy...